Contributions
Abstract: P1165
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Introduction: Cognitive impairment has a major negative impact on the lives of people with MS, but until recently routine clinical assessment and management was rarely available, due to lack of suitable scales. The Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) is a 15 minute tool, requiring little specialist equipment, which can be implemented by most health professionals. It assesses information processing speed (Symbol Digit Modality Test, SDMT); verbal recall (California Verbal Learning Test II, CVLT II, five recall trials); and visual memory (Brief Verbal Memory Test - Revised, BVMT-R, three recall trials). BICAMS is becoming accepted as an international standard.
Objectives: To complete a systematic review and meta-analysis on the published national BICAMS validations.
Aim: The aim of this systematic review and meta-analysis was to synthesise the available literature which have been published as part of the BICAMS international validation protocol.
Method: A literature search conducted using PubMed, PsychoInfo and Google Scholar identified 16 studies for inclusion in the systematic review and 14 of those which could be included in the meta-analysis.
Results: BICAMS has been widely validated across 11 different languages and 14 individual cultures and locations (America, Argentina (two papers), Belgium, Brazil, Canada, Czechoslovakia, Greece, Hungary, Iran, Ireland, Italy (two papers), Japan, and Lithuania and Turkey). The meta-analysis demonstrated that BICAMS identified significantly reduced cognitive functioning in adults with MS, compared to matched healthy control participants. This was true for all three cognitive domains assessed by BICAMS: information processing speed (SDMT, g = 0.946, 95% CI = 0.843, 1.050, p < .001), immediate verbal recall memory (CVLT-II, g = 0.674, 95% CI = 0.541, 0.808, p < .001) and immediate visual recall memory (BVMT-R, g = 0.638, 95% CI = 0.537, 0.739, p < .001).
Conclusions: BICAMS has been widely adopted across many cultures and languages to assess cognition in MS and been shown to be an effective assessment. BICAMS offers a cost-effective, feasible means of assessing cognition in MS worldwide. Further validation studies are underway to support this project.
Disclosure: FC: nothing to disclose.
DL: Consultancy from Novartis, Bayer, TEVA, Biogen, Merck; Speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer, Excemed; Research grants from Novartis, Biogen, Bayer, Merck. All are paid into DL's university.
Abstract: P1165
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Introduction: Cognitive impairment has a major negative impact on the lives of people with MS, but until recently routine clinical assessment and management was rarely available, due to lack of suitable scales. The Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) is a 15 minute tool, requiring little specialist equipment, which can be implemented by most health professionals. It assesses information processing speed (Symbol Digit Modality Test, SDMT); verbal recall (California Verbal Learning Test II, CVLT II, five recall trials); and visual memory (Brief Verbal Memory Test - Revised, BVMT-R, three recall trials). BICAMS is becoming accepted as an international standard.
Objectives: To complete a systematic review and meta-analysis on the published national BICAMS validations.
Aim: The aim of this systematic review and meta-analysis was to synthesise the available literature which have been published as part of the BICAMS international validation protocol.
Method: A literature search conducted using PubMed, PsychoInfo and Google Scholar identified 16 studies for inclusion in the systematic review and 14 of those which could be included in the meta-analysis.
Results: BICAMS has been widely validated across 11 different languages and 14 individual cultures and locations (America, Argentina (two papers), Belgium, Brazil, Canada, Czechoslovakia, Greece, Hungary, Iran, Ireland, Italy (two papers), Japan, and Lithuania and Turkey). The meta-analysis demonstrated that BICAMS identified significantly reduced cognitive functioning in adults with MS, compared to matched healthy control participants. This was true for all three cognitive domains assessed by BICAMS: information processing speed (SDMT, g = 0.946, 95% CI = 0.843, 1.050, p < .001), immediate verbal recall memory (CVLT-II, g = 0.674, 95% CI = 0.541, 0.808, p < .001) and immediate visual recall memory (BVMT-R, g = 0.638, 95% CI = 0.537, 0.739, p < .001).
Conclusions: BICAMS has been widely adopted across many cultures and languages to assess cognition in MS and been shown to be an effective assessment. BICAMS offers a cost-effective, feasible means of assessing cognition in MS worldwide. Further validation studies are underway to support this project.
Disclosure: FC: nothing to disclose.
DL: Consultancy from Novartis, Bayer, TEVA, Biogen, Merck; Speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer, Excemed; Research grants from Novartis, Biogen, Bayer, Merck. All are paid into DL's university.